Skip to main content

News

ICYMI: 9 Facts about Leflunomide

Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. Here are some highpoints from this Medscape article and lecture.

ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis

An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).

ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).

ICYMI: JAMA: SLE Review

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

ICYMI: BSR Guideline on Management of Sjogren’s Syndrome

Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations. The British Society of Rheumatology has updated its 2017 guidelines, with wider evidence and recommendations for the management of children and adolescents with SD. This article reviews the data and recommendations stemming from 19 questions on SD care.

Future Big BiTEs (6.28.2024)

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Factors Affecting Hydroxychloroquine Adherence

A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. 

JAK Inhibitors in Giant Cell Arteritis

Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care.

Difficult-to-Treat Psoriasis

This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.

Low Back Pain? Take a Walk!

A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis

A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.
×